{"id":"https://openalex.org/W2891925600","doi":"https://doi.org/10.1158/1535-7163.mct-17-1104","title":"Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy","display_name":"Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy","alternate_titles":[],"publication_year":2018,"publication_date":"2018-09-20","ids":{"openalex":"https://openalex.org/W2891925600","doi":"https://doi.org/10.1158/1535-7163.mct-17-1104","mag":"2891925600","pmid":"https://pubmed.ncbi.nlm.nih.gov/30232146"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.mct-17-1104","doi":"https://doi.org/10.1158/1535-7163.mct-17-1104","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-17-1104","pdf_url":"https://aacrjournals.org/mct/article-pdf/17/12/2530/1856933/2530.pdf","source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2891925600"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://aacrjournals.org/mct/article-pdf/17/12/2530/1856933/2530.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5042409986","display_name":"Bruno Gomes","orcid":"https://orcid.org/0000-0002-5569-0526","observed_orcids":["https://orcid.org/0000-0002-5569-0526"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Bruno Gomes","raw_affiliation_strings":["1iTeos Therapeutics SA, Gosselies, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1iTeos Therapeutics SA, Gosselies, Belgium","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002197682","display_name":"Gr\u00e9gory Driessens","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Gregory Driessens","raw_affiliation_strings":["1iTeos Therapeutics SA, Gosselies, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1iTeos Therapeutics SA, Gosselies, Belgium","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075849487","display_name":"Derek W. Bartlett","orcid":"https://orcid.org/0000-0001-8099-9069","observed_orcids":["https://orcid.org/0000-0001-8099-9069"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Derek Bartlett","raw_affiliation_strings":["2Pfizer Inc., San Diego, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Pfizer Inc., San Diego, California","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109449162","display_name":"Danying Cai","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210115256","display_name":"Jackson Laboratory","ror":"https://ror.org/021sy4w91","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210115256"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Danying Cai","raw_affiliation_strings":["3The Jackson Laboratory, Sacramento, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3The Jackson Laboratory, Sacramento, California","institution_ids":["https://openalex.org/I4210115256"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032888152","display_name":"Sandra Cauwenberghs","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sandra Cauwenberghs","raw_affiliation_strings":["1iTeos Therapeutics SA, Gosselies, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1iTeos Therapeutics SA, Gosselies, Belgium","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071595199","display_name":"Stefano Crosignani","orcid":"https://orcid.org/0009-0009-6316-3265","observed_orcids":["https://orcid.org/0009-0009-6316-3265"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Stefano Crosignani","raw_affiliation_strings":["1iTeos Therapeutics SA, Gosselies, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1iTeos Therapeutics SA, Gosselies, Belgium","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047357717","display_name":"Deepak Dalvie","orcid":"https://orcid.org/0000-0001-6196-5314","observed_orcids":["https://orcid.org/0000-0001-6196-5314"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Deepak Dalvie","raw_affiliation_strings":["2Pfizer Inc., San Diego, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Pfizer Inc., San Diego, California","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091214474","display_name":"Sofie Denies","orcid":"https://orcid.org/0009-0008-0019-8025","observed_orcids":["https://orcid.org/0009-0008-0019-8025"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sofie Denies","raw_affiliation_strings":["1iTeos Therapeutics SA, Gosselies, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1iTeos Therapeutics SA, Gosselies, Belgium","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079880890","display_name":"Christopher P. Dillon","orcid":"https://orcid.org/0000-0002-9458-0266","observed_orcids":["https://orcid.org/0000-0002-9458-0266"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Christopher P. Dillon","raw_affiliation_strings":["2Pfizer Inc., San Diego, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Pfizer Inc., San Diego, California","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059897477","display_name":"Valeria R. Fantin","orcid":"https://orcid.org/0009-0005-8328-0152","observed_orcids":["https://orcid.org/0009-0005-8328-0152"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Valeria R. Fantin","raw_affiliation_strings":["2Pfizer Inc., San Diego, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Pfizer Inc., San Diego, California","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103219249","display_name":"Jie Guo","orcid":"https://orcid.org/0000-0003-3605-9891","observed_orcids":["https://orcid.org/0000-0003-3605-9891"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jie Guo","raw_affiliation_strings":["2Pfizer Inc., San Diego, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Pfizer Inc., San Diego, California","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024323910","display_name":"Marie-Claire Letellier","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Marie-Claire Letellier","raw_affiliation_strings":["1iTeos Therapeutics SA, Gosselies, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1iTeos Therapeutics SA, Gosselies, Belgium","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020133148","display_name":"Wenlin Li","orcid":"https://orcid.org/0000-0002-0842-222X","observed_orcids":["https://orcid.org/0000-0002-0842-222X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Wenlin Li","raw_affiliation_strings":["2Pfizer Inc., San Diego, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Pfizer Inc., San Diego, California","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071409456","display_name":"Karen A. Maegley","orcid":"https://orcid.org/0000-0002-5467-3177","observed_orcids":["https://orcid.org/0000-0002-5467-3177"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Karen Maegley","raw_affiliation_strings":["2Pfizer Inc., San Diego, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Pfizer Inc., San Diego, California","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084946547","display_name":"Reece G. Marillier","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Reece Marillier","raw_affiliation_strings":["1iTeos Therapeutics SA, Gosselies, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1iTeos Therapeutics SA, Gosselies, Belgium","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058150315","display_name":"Nichol L. G. Miller","orcid":"https://orcid.org/0000-0002-4805-3385","observed_orcids":["https://orcid.org/0000-0002-4805-3385"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Nichol Miller","raw_affiliation_strings":["2Pfizer Inc., San Diego, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Pfizer Inc., San Diego, California","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087148709","display_name":"Romain Pirson","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Romain Pirson","raw_affiliation_strings":["1iTeos Therapeutics SA, Gosselies, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1iTeos Therapeutics SA, Gosselies, Belgium","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112211134","display_name":"Virginie Rabolli","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Virginie Rabolli","raw_affiliation_strings":["1iTeos Therapeutics SA, Gosselies, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1iTeos Therapeutics SA, Gosselies, Belgium","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022553469","display_name":"CHAD A. RAY","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Chad Ray","raw_affiliation_strings":["2Pfizer Inc., San Diego, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Pfizer Inc., San Diego, California","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013106114","display_name":"Nicole Streiner","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Nicole Streiner","raw_affiliation_strings":["2Pfizer Inc., San Diego, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Pfizer Inc., San Diego, California","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075323544","display_name":"Vince R. Torti","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Vince R. Torti","raw_affiliation_strings":["2Pfizer Inc., San Diego, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Pfizer Inc., San Diego, California","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000804175","display_name":"Konstantinos E. Tsaparikos","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Konstantinos Tsaparikos","raw_affiliation_strings":["2Pfizer Inc., San Diego, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Pfizer Inc., San Diego, California","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110511175","display_name":"Benoit J. Van den Eynde","orcid":"https://orcid.org/0000-0002-4995-3270","observed_orcids":["https://orcid.org/0000-0002-4995-3270"]},"institutions":[{"id":"https://openalex.org/I196064397","display_name":"Ludwig Cancer Research","ror":"https://ror.org/05923xh51","country_code":"BE","type":"nonprofit","lineage":["https://openalex.org/I196064397","https://openalex.org/I4210150094"]},{"id":"https://openalex.org/I4210114657","display_name":"de Duve Institute","ror":"https://ror.org/022em3k58","country_code":"BE","type":"facility","lineage":["https://openalex.org/I4210114657"]},{"id":"https://openalex.org/I95674353","display_name":"UCLouvain","ror":"https://ror.org/02495e989","country_code":"BE","type":"education","lineage":["https://openalex.org/I95674353"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"Benoit J. Van den Eynde","raw_affiliation_strings":["1iTeos Therapeutics SA, Gosselies, Belgium","4Ludwig Institute for Cancer Research, de Duve Institute, Universit\u00e9 catholique de Louvain, Brussels, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1iTeos Therapeutics SA, Gosselies, Belgium","institution_ids":[]},{"raw_affiliation_string":"4Ludwig Institute for Cancer Research, de Duve Institute, Universit\u00e9 catholique de Louvain, Brussels, Belgium","institution_ids":["https://openalex.org/I196064397","https://openalex.org/I4210114657","https://openalex.org/I95674353"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063500857","display_name":"Martin J. Wythes","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Martin Wythes","raw_affiliation_strings":["2Pfizer Inc., San Diego, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Pfizer Inc., San Diego, California","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112905649","display_name":"Li\u2010Chin Yao","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210115256","display_name":"Jackson Laboratory","ror":"https://ror.org/021sy4w91","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210115256"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Li-Chin Yao","raw_affiliation_strings":["3The Jackson Laboratory, Sacramento, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3The Jackson Laboratory, Sacramento, California","institution_ids":["https://openalex.org/I4210115256"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100942371","display_name":"Xianxian Zheng","orcid":"https://orcid.org/0000-0001-7836-0442","observed_orcids":["https://orcid.org/0000-0001-7836-0442"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Xianxian Zheng","raw_affiliation_strings":["2Pfizer Inc., San Diego, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Pfizer Inc., San Diego, California","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035122235","display_name":"Joseph R. Tumang","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Joseph Tumang","raw_affiliation_strings":["2Pfizer Inc., San Diego, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Pfizer Inc., San Diego, California","institution_ids":[]}]},{"author_position":"last","author":{"id":null,"display_name":"Manfred Kraus","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Manfred Kraus","raw_affiliation_strings":["2Pfizer Inc., San Diego, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Pfizer Inc., San Diego, California","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5002197682"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":3.5535,"has_fulltext":true,"cited_by_count":90,"citation_normalized_percentile":{"value":0.95507208,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":96,"max":99},"biblio":{"volume":"17","issue":"12","first_page":"2530","last_page":"2542"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9897000193595886,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9897000193595886,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.003700000001117587,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10031","display_name":"T-cell and B-cell Immunology","score":0.000699999975040555,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ido1","display_name":"IDO1","score":0.9570000171661377},{"id":"https://openalex.org/keywords/ido1-inhibitors","display_name":"IDO1 inhibitors","score":0.8019999861717224},{"id":"https://openalex.org/keywords/pd-l1-blockade","display_name":"PD-L1 blockade","score":0.8790000081062317},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitor-resistance","display_name":"immune checkpoint inhibitor resistance","score":0.6359999775886536},{"id":"https://openalex.org/keywords/kynurenine","display_name":"kynurenine","score":0.8119999766349792},{"id":"https://openalex.org/keywords/tryptophan-catabolism","display_name":"tryptophan catabolism","score":0.9150000214576721},{"id":"https://openalex.org/keywords/t-cell-anergy","display_name":"T cell anergy","score":0.8999999761581421},{"id":"https://openalex.org/keywords/tumor-immunosuppression","display_name":"tumor immunosuppression","score":0.7749999761581421},{"id":"https://openalex.org/keywords/combination-immunotherapy","display_name":"combination immunotherapy","score":0.7749999761581421},{"id":"https://openalex.org/keywords/oral-bioavailability","display_name":"oral bioavailability","score":0.6679999828338623},{"id":"https://openalex.org/keywords/tumor-microenvironment","display_name":"tumor microenvironment","score":0.5580000281333923}],"concepts":[{"id":"https://openalex.org/C83478079","wikidata":"https://www.wikidata.org/wiki/Q908221","display_name":"Indoleamine 2,3-dioxygenase","level":4,"score":0.7111422419548035},{"id":"https://openalex.org/C2777503454","wikidata":"https://www.wikidata.org/wiki/Q415768","display_name":"Kynurenine","level":4,"score":0.693052351474762},{"id":"https://openalex.org/C2776107976","wikidata":"https://www.wikidata.org/wiki/Q1786433","display_name":"Tumor microenvironment","level":3,"score":0.6654797792434692},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.6275977492332458},{"id":"https://openalex.org/C2780851360","wikidata":"https://www.wikidata.org/wiki/Q21686041","display_name":"Immune checkpoint","level":4,"score":0.5532330274581909},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5501053929328918},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.5275708436965942},{"id":"https://openalex.org/C2779727006","wikidata":"https://www.wikidata.org/wiki/Q426188","display_name":"FOXP3","level":3,"score":0.49595698714256287},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.480295866727829},{"id":"https://openalex.org/C2777702733","wikidata":"https://www.wikidata.org/wiki/Q1356761","display_name":"Immune tolerance","level":3,"score":0.47854405641555786},{"id":"https://openalex.org/C2776090121","wikidata":"https://www.wikidata.org/wiki/Q193529","display_name":"T cell","level":3,"score":0.45959290862083435},{"id":"https://openalex.org/C127561419","wikidata":"https://www.wikidata.org/wiki/Q224527","display_name":"Downregulation and upregulation","level":3,"score":0.45461520552635193},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.3992847204208374},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.3488166928291321},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.33383697271347046},{"id":"https://openalex.org/C2776706248","wikidata":"https://www.wikidata.org/wiki/Q181003","display_name":"Tryptophan","level":3,"score":0.14490807056427002},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.1062556803226471},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C515207424","wikidata":"https://www.wikidata.org/wiki/Q8066","display_name":"Amino acid","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D004791","descriptor_name":"Enzyme Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007167","descriptor_name":"Immunotherapy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D007211","descriptor_name":"Indoles","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D007371","descriptor_name":"Interferon-gamma","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D007737","descriptor_name":"Kynurenine","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D008807","descriptor_name":"Mice, Inbred BALB C","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008810","descriptor_name":"Mice, Inbred C57BL","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013237","descriptor_name":"Stereoisomerism","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013379","descriptor_name":"Substrate Specificity","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D013388","descriptor_name":"Succinimides","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D013601","descriptor_name":"T-Lymphocytes","qualifier_ui":"Q000166","qualifier_name":"cytology","is_major_topic":false},{"descriptor_ui":"D013601","descriptor_name":"T-Lymphocytes","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D016246","descriptor_name":"Lymphocytes, Tumor-Infiltrating","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D045744","descriptor_name":"Cell Line, Tumor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D049109","descriptor_name":"Cell Proliferation","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D050503","descriptor_name":"Indoleamine-Pyrrole 2,3,-Dioxygenase","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D050503","descriptor_name":"Indoleamine-Pyrrole 2,3,-Dioxygenase","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D055162","descriptor_name":"Biocatalysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D060890","descriptor_name":"B7-H1 Antigen","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D060890","descriptor_name":"B7-H1 Antigen","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D060908","descriptor_name":"CTLA-4 Antigen","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":5,"locations":[{"id":"doi:10.1158/1535-7163.mct-17-1104","doi":"https://doi.org/10.1158/1535-7163.mct-17-1104","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-17-1104","pdf_url":"https://aacrjournals.org/mct/article-pdf/17/12/2530/1856933/2530.pdf","source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},{"id":"pmid:30232146","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/30232146","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular cancer therapeutics","raw_type":"Journal Article"},{"id":"pmh:oai:ora.ox.ac.uk:uuid:0d4fbf62-5a29-4242-9a49-40407c657439","doi":null,"is_oa":true,"landing_page_url":"https://ora.ox.ac.uk/objects/uuid:0d4fbf62-5a29-4242-9a49-40407c657439","pdf_url":"https://ora.ox.ac.uk/objects/uuid:0d4fbf62-5a29-4242-9a49-40407c657439/files/m1b3852c82f9094cf4c49f94a25844993","source":{"id":"https://openalex.org/S4306402636","display_name":"Oxford University Research Archive (ORA) (University of Oxford)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I40120149","host_organization_name":"University of Oxford","host_organization_lineage":["https://openalex.org/I40120149"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"Symplectic Elements at Oxford","raw_type":"Journal article"},{"id":"pmh:oai:dial.uclouvain.be:boreal:213631","doi":null,"is_oa":false,"landing_page_url":"http://hdl.handle.net/2078.1/213631","pdf_url":null,"source":{"id":"https://openalex.org/S4306400166","display_name":"Digital Access to Libraries","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I2800384882","host_organization_name":"Harris County Public Library","host_organization_lineage":["https://openalex.org/I2800384882"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Molecular Cancer Therapeutics, Vol. 17, no.12, p. 2530-2542 (2018)","raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:oai:mouseion.jax.org:stfb2018-1242","doi":null,"is_oa":false,"landing_page_url":"https://mouseion.jax.org/stfb2018/241","pdf_url":null,"source":{"id":"https://openalex.org/S4377196421","display_name":"The Mouseion at the JAXlibrary (Jackson Laboratory)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210115256","host_organization_name":"Jackson Laboratory","host_organization_lineage":["https://openalex.org/I4210115256"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Faculty Research 2018","raw_type":"text"}],"best_oa_location":{"id":"doi:10.1158/1535-7163.mct-17-1104","doi":"https://doi.org/10.1158/1535-7163.mct-17-1104","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-17-1104","pdf_url":"https://aacrjournals.org/mct/article-pdf/17/12/2530/1856933/2530.pdf","source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9763000011444092}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307765","display_name":"Pfizer","ror":"https://ror.org/01xdqrp08"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2891925600.pdf","grobid_xml":"https://content.openalex.org/works/W2891925600.grobid-xml"},"referenced_works_count":39,"referenced_works":["https://openalex.org/W1505072916","https://openalex.org/W1603640418","https://openalex.org/W1913780655","https://openalex.org/W1942897646","https://openalex.org/W1973251492","https://openalex.org/W1975929837","https://openalex.org/W1991075838","https://openalex.org/W1991344565","https://openalex.org/W2007489575","https://openalex.org/W2008343182","https://openalex.org/W2010378562","https://openalex.org/W2022430924","https://openalex.org/W2024000351","https://openalex.org/W2038234028","https://openalex.org/W2054475219","https://openalex.org/W2072078248","https://openalex.org/W2087801719","https://openalex.org/W2103553504","https://openalex.org/W2104065243","https://openalex.org/W2113325722","https://openalex.org/W2113846910","https://openalex.org/W2113906692","https://openalex.org/W2122285073","https://openalex.org/W2126932404","https://openalex.org/W2127903252","https://openalex.org/W2134670672","https://openalex.org/W2153599751","https://openalex.org/W2167897482","https://openalex.org/W2298272175","https://openalex.org/W2418696831","https://openalex.org/W2553568639","https://openalex.org/W2570766240","https://openalex.org/W2589004473","https://openalex.org/W2599400888","https://openalex.org/W2741622689","https://openalex.org/W2767640831","https://openalex.org/W2768987490","https://openalex.org/W6663828621","https://openalex.org/W6746079934"],"related_works":["https://openalex.org/W2480979408","https://openalex.org/W2485876986","https://openalex.org/W4293581628","https://openalex.org/W2767640831","https://openalex.org/W2741787889","https://openalex.org/W4211145083","https://openalex.org/W2566323665","https://openalex.org/W2800712256","https://openalex.org/W2763945364","https://openalex.org/W2902685760"],"abstract_inverted_index":{"Abstract":[0],"Tumors":[1],"use":[2],"indoleamine":[3],"2,3-dioxygenase-1":[4],"(IDO1)":[5],"as":[6,42],"a":[7,26,76,191],"major":[8],"mechanism":[9,28],"to":[10,24,29,38,63],"induce":[11],"an":[12,87,139],"immunosuppressive":[13,83],"microenvironment.":[14,60],"IDO1":[15,33,85,106,160,173],"expression":[16],"is":[17,34],"upregulated":[18],"in":[19,36,57,91,114,135,142,158,175],"many":[20],"cancers":[21],"and":[22,44,51,67,98,130,183],"considered":[23],"be":[25],"resistance":[27],"immune":[30,46,148],"checkpoint":[31,149],"therapies.":[32],"induced":[35],"response":[37],"inflammatory":[39],"stimuli":[40],"such":[41],"IFN\u03b3":[43],"promotes":[45],"tolerance":[47],"by":[48,127,179],"depleting":[49],"tryptophan":[50,53],"producing":[52],"catabolites,":[54],"including":[55],"kynurenine,":[56],"the":[58,79,96,101,147],"tumor":[59,120,132],"This":[61],"leads":[62],"effector":[64],"T-cell":[65,112],"anergy":[66,113],"enhanced":[68],"Treg":[69],"function":[70],"through":[71],"upregulation":[72],"of":[73,81,100,189],"FoxP3.":[74],"As":[75],"nexus":[77],"for":[78,168],"induction":[80],"key":[82],"mechanisms,":[84],"represents":[86],"important":[88],"immunotherapeutic":[89],"target":[90],"oncology.":[92],"Here,":[93],"we":[94],"report":[95],"identification":[97],"characterization":[99],"novel":[102],"selective,":[103],"orally":[104],"bioavailable":[105],"inhibitor":[107],"EOS200271/PF-06840003.":[108],"It":[109],"reversed":[110],"IDO1-induced":[111],"vitro.":[115],"In":[116],"mice":[117],"carrying":[118],"syngeneic":[119],"grafts,":[121],"PF-06840003":[122],"reduced":[123],"intratumoral":[124],"kynurenine":[125],"levels":[126],"over":[128],"80%":[129],"inhibited":[131],"growth":[133],"both":[134],"monotherapy":[136],"and,":[137],"with":[138,144,172],"increased":[140,159],"efficacy,":[141],"combination":[143],"antibodies":[145],"blocking":[146],"ligand":[150],"PD-L1.":[151],"We":[152],"demonstrate":[153],"that":[154],"anti\u2013PD-L1":[155],"therapy":[156],"results":[157],"metabolic":[161],"activity":[162],"thereby":[163],"providing":[164],"additional":[165],"mechanistic":[166],"rationale":[167],"combining":[169],"PD-(L)1":[170],"blockade":[171],"inhibition":[174],"cancer":[176],"immunotherapies.":[177],"Supported":[178],"these":[180],"preclinical":[181],"data":[182],"favorable":[184],"predicted":[185],"human":[186],"pharmacokinetic":[187],"properties":[188],"PF-06840003,":[190],"phase":[192],"I":[193],"open-label,":[194],"multicenter":[195],"clinical":[196],"study":[197],"(NCT02764151)":[198],"has":[199],"been":[200],"initiated.":[201]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2891925600","counts_by_year":[{"year":2026,"cited_by_count":9},{"year":2025,"cited_by_count":9},{"year":2024,"cited_by_count":13},{"year":2023,"cited_by_count":10},{"year":2022,"cited_by_count":12},{"year":2021,"cited_by_count":18},{"year":2020,"cited_by_count":15},{"year":2019,"cited_by_count":4}],"updated_date":"2026-11-17T12:49:18.490984","created_date":"2018-09-27T00:00:00"}
